Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Collyar: What's In It for Patients?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Aug
20
Today In Oncology
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events
Charles WM Roberts Named President and Chief Executive Officer of St. Jude Children’s Research Hospital
Is Excess Adiposity Linked to Vertebral Fracture Progression in Aromatase Inhibitor–Treated Early Breast Cancer?
Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo